Bris­tol My­ers bets on neu­ro­science surge with $14B Karuna cash ac­qui­si­tion

Bris­tol My­ers Squibb will buy CNS drug­mak­er Karuna Ther­a­peu­tics for cash in a deal val­ued at $14 bil­lion, the com­pa­nies an­nounced Fri­day morn­ing.

The move comes a few weeks af­ter Ab­b­Vie signed its own $8.7 bil­lion deal for a neu­ro­science drug­mak­er, the fur­ther be­hind Cerev­el Ther­a­peu­tics. Both are de­vel­op­ing a new type of schiz­o­phre­nia drug, with the FDA set to de­cide on Karuna’s KarXT by Sept. 26, 2024, while Cerev­el is in late-stage clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER